Why Attend


The Premier Virtual Partnering Event of 2021

Biocom’s top priority is the safety of our members and the well-being of our employees. After careful consideration, Biocom has decided to transform our 2021 Global Life Science Partnering Conference to a fully virtual event. We know that many lives are being impacted and disrupted by COVID-19 and we are grateful to be able to continue offering our members valuable content in a safe manner.

Biocom’s 11th Annual Global Life Science Partnering Conference will be completely virtual and is an exclusive global partnering forum that brings together senior executives, bankers, venture capitalists, and business development professionals from leading pharmaceutical and biotech companies. Join us February 23rd to 25th, 2021, where industry leaders will debate current trends, companies will showcase their latest technologies and all attendees will have the opportunity to schedule one-on-one meetings with leading deal-makers.

The partnering conference and the relationships you build promise to be fruitful for your business ventures this year and for many years to come. We are excited by the prospect of continuing an annual bio-pharma partnering conference that brings together leading deal makers and emerging biotechs from around the world.

Join us in February 2021, where industry leaders will debate current trends, companies will showcase their latest technologies and all attendees will have the opportunity to schedule virtual one-on-one meetings with leading dealmakers from around the globe.


Attendee Benefits:

IndustryAttendeeDemographic_GPC    RegionalDemographic_GPC

Hear What Others Have to Say:

“Every partnering meeting was great and all the panels were beyond fantastic. I even met a new investor!”
Ross Bundy, CEO, Nanomedical Diagnostics

“Presenting at Biocom this year helped put Forge on the radar of several investors seeking to put money to work in the antibiotic space. The conference not only gave me the opportunity to meet the interested investors face-to-face but also gave me a platform to describe our funding strategy and growth trajectory, which gave us additional momentum leading to upsizing our Series A round. In fact, after my presentation multiple investors that were ‘circling the hoop’ were now ready to jump into the game and asked if they could participate in the Series A financing.”
Zachary Zimmerman, Ph.D., CEO , Forge Therapeutics, Inc.